A new trading day began on Friday, with Quince Therapeutics Inc (NASDAQ: QNCX) stock price down -5.77% from the previous day of trading, before settling in for the closing price of $2.08. QNCX’s price has ranged from $0.51 to $2.14 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
With a float of $32.62 million, this company’s outstanding shares have now reached $42.97 million.
Let’s look at the performance matrix of the company that is accounted for 32 employees. In terms of profitability, gross margin is -977.78%, operating margin of -134919.44%, and the pretax margin is -147591.67%.
Quince Therapeutics Inc (QNCX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Quince Therapeutics Inc is 25.87%, while institutional ownership is 11.40%. The most recent insider transaction that took place on Aug 30 ’24, was worth 53,900. In this transaction CEO AND CHIEF MEDICAL OFFICER of this company bought 77,000 shares at a rate of $0.70, taking the stock ownership to the 843,941 shares. Before that another transaction happened on Aug 29 ’24, when Company’s CEO AND CHIEF MEDICAL OFFICER bought 77,500 for $0.69, making the entire transaction worth $53,475. This insider now owns 766,941 shares in total.
Quince Therapeutics Inc (QNCX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.30% during the next five years compared to -12.64% drop over the previous five years of trading.
Quince Therapeutics Inc (NASDAQ: QNCX) Trading Performance Indicators
Here are Quince Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.25, a number that is poised to hit -0.18 in the next quarter
Technical Analysis of Quince Therapeutics Inc (QNCX)
Quince Therapeutics Inc (NASDAQ: QNCX) saw its 5-day average volume 0.36 million, a positive change from its year-to-date volume of 0.23 million. As of the previous 9 days, the stock’s Stochastic %D was 62.70%. Additionally, its Average True Range was 0.25.
During the past 100 days, Quince Therapeutics Inc’s (QNCX) raw stochastic average was set at 74.72%, which indicates a significant increase from 53.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.03% in the past 14 days, which was higher than the 108.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1257, while its 200-day Moving Average is $0.9608. Nevertheless, the first resistance level for the watch stands at $2.3800 in the near term. At $2.8000, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.1500. If the price goes on to break the first support level at $1.6100, it is likely to go to the next support level at $1.2600. Assuming the price breaks the second support level, the third support level stands at $0.8400.
Quince Therapeutics Inc (NASDAQ: QNCX) Key Stats
With a market capitalization of 81.26 million, the company has a total of 44,002K Shares Outstanding. Currently, annual sales are 0 K while annual income is -31,390 K. The company’s previous quarter sales were 0 K while its latest quarter income was -5,490 K.
